Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,priceHint,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,shortName,marketState,market,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,forwardPE,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,GRTS,178825000.0,49197800,,,-25118000,,-25118000,5937000,-19229000,-25166000,-25166000,,,,,,0,2843000,28009000,22072000,48000,,-25118000,-25118000,522290000.0,45399000.0,178825000.0,2940000.0,224224000.0,18000.0,336000.0,-343497000.0,7796000.0,14000.0,2976000.0,64081000.0,21427000.0,14000.0,40492000.0,176755000.0,4001000.0,107101000.0,2470000.0,4795000.0,-21817000,-2061000,-23487000,1745000,-1991000,1888000,-44424000,-22682000,1598000,-143000,4890000,-1670000,155328000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NMS,9.55,1630526402,0.35000038,9.18,9.59,9.15,604221,0,"Gritstone bio, Inc.",PREPRE,us_market,0.5235622,1630540710,9.6,0.05000019,3.804352,9.15 - 9.59,9.2,0.0,0.0,29,18,finmb_314744798,NasdaqGS,"Gritstone bio, Inc.",USD,632979,609728,7.01,2.7598426,2.54 - 35.2,-25.650002,-0.7286932,2.54,35.2,1620291660,1620291660,1620291660,0.22881515,9.795073,-0.24507236,-0.025019964,-3.9139345,-1.449,-2.44,-1.27,-7.5196853,4.052,7.771714,1.778286,469839008,2.3568609,15,America/New_York,EDT,-14400000,False,False,0.11,,,35.2,2.54,7.77,9.8,632.98k,609.73k,49.2M,,37.47M,3.77%,70.97%,5.54M,11.22,13.76%,11.21%,4.82M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-157.14%,-157.42%,-23.84%,-51.21%,44.82M,0.78,482.60%,-84.61M,-64M,-70.44M,-1.45,,171.18M,3.46,22.35M,12.50,8.25,4.05,-57.42M,-35.29M,Value,94608,Healthcare,181,9,6,"Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was founded in 2015 and is headquartered in Emeryville, California.",EmeryVille,510 871 6100,CA,8,1609372800,1625097600,7,United States,http://gritstonebio.com,86400,8,5959 Horton Street,510 597 1488,Biotechnology,Suite 300
t-1,GRTS,199351000.0,49197800,,,7923000,,7923000,6941000,14837000,7896000,7896000,,,,,,0,39693000,31797000,24856000,27000,,7923000,7923000,517715000.0,47588000.0,199351000.0,3386000.0,246939000.0,18000.0,513000.0,-318379000.0,8190000.0,-3000.0,2736000.0,108505000.0,21779000.0,-3000.0,41690000.0,202513000.0,,89501000.0,249000.0,6368000.0,-88610000,1123000,-89600000,17395000,-4195000,23273000,-61551000,10654000,1595000,-5878000,4208000,-990000,180734000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NMS,9.55,1630526402,0.35000038,9.18,9.59,9.15,604221,0,"Gritstone bio, Inc.",PREPRE,us_market,0.5235622,1630540710,9.6,0.05000019,3.804352,9.15 - 9.59,9.2,0.0,0.0,29,18,finmb_314744798,NasdaqGS,"Gritstone bio, Inc.",USD,632979,609728,7.01,2.7598426,2.54 - 35.2,-25.650002,-0.7286932,2.54,35.2,1620291660,1620291660,1620291660,0.22881515,9.795073,-0.24507236,-0.025019964,-3.9139345,-1.449,-2.44,-1.27,-7.5196853,4.052,7.771714,1.778286,469839008,2.3568609,15,America/New_York,EDT,-14400000,False,False,0.11,,,35.2,2.54,7.77,9.8,632.98k,609.73k,49.2M,,37.47M,3.77%,70.97%,5.54M,11.22,13.76%,11.21%,4.82M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-157.14%,-157.42%,-23.84%,-51.21%,44.82M,0.78,482.60%,-84.61M,-64M,-70.44M,-1.45,,171.18M,3.46,22.35M,12.50,8.25,4.05,-57.42M,-35.29M,Value,94608,Healthcare,181,9,6,"Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was founded in 2015 and is headquartered in Emeryville, California.",EmeryVille,510 871 6100,CA,8,1609372800,1625097600,7,United States,http://gritstonebio.com,86400,8,5959 Horton Street,510 597 1488,Biotechnology,Suite 300
t-2,GRTS,166739000.0,49197800,,,-27167000,,-27167000,5660000,-21487000,-27147000,-27147000,,-142000.0,,,,0,1349000,28496000,22836000,-20000,,-27167000,-27167000,493023000.0,54828000.0,166739000.0,3571000.0,221567000.0,18000.0,268000.0,-326302000.0,8615000.0,,2728000.0,170056000.0,26988000.0,,43449000.0,175390000.0,,1002000.0,,9578000.0,11890000,107000,11618000,125432000,-3436000,125432000,111833000,-25217000,1693000,-5878000,3586000,-272000,148402000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NMS,9.55,1630526402,0.35000038,9.18,9.59,9.15,604221,0,"Gritstone bio, Inc.",PREPRE,us_market,0.5235622,1630540710,9.6,0.05000019,3.804352,9.15 - 9.59,9.2,0.0,0.0,29,18,finmb_314744798,NasdaqGS,"Gritstone bio, Inc.",USD,632979,609728,7.01,2.7598426,2.54 - 35.2,-25.650002,-0.7286932,2.54,35.2,1620291660,1620291660,1620291660,0.22881515,9.795073,-0.24507236,-0.025019964,-3.9139345,-1.449,-2.44,-1.27,-7.5196853,4.052,7.771714,1.778286,469839008,2.3568609,15,America/New_York,EDT,-14400000,False,False,0.11,,,35.2,2.54,7.77,9.8,632.98k,609.73k,49.2M,,37.47M,3.77%,70.97%,5.54M,11.22,13.76%,11.21%,4.82M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-157.14%,-157.42%,-23.84%,-51.21%,44.82M,0.78,482.60%,-84.61M,-64M,-70.44M,-1.45,,171.18M,3.46,22.35M,12.50,8.25,4.05,-57.42M,-35.29M,Value,94608,Healthcare,181,9,6,"Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was founded in 2015 and is headquartered in Emeryville, California.",EmeryVille,510 871 6100,CA,8,1609372800,1625097600,7,United States,http://gritstonebio.com,86400,8,5959 Horton Street,510 597 1488,Biotechnology,Suite 300
t-3,GRTS,71984000.0,49197800,,,-26073000,,-26073000,5031000,-21111000,-26142000,-26142000,,-142000.0,,,,0,939000,27081000,22050000,69000,,-26073000,-26073000,371097000.0,50524000.0,71984000.0,5528000.0,122508000.0,17000.0,978000.0,-299135000.0,7720000.0,5000.0,2749000.0,57648000.0,22013000.0,5000.0,46012000.0,73747000.0,,12897000.0,61000.0,3284000.0,16350000,-1593000,15732000,37000,2077000,38000,-4408000,-20177000,1674000,-1000,3738000,-618000,51734000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NMS,9.55,1630526402,0.35000038,9.18,9.59,9.15,604221,0,"Gritstone bio, Inc.",PREPRE,us_market,0.5235622,1630540710,9.6,0.05000019,3.804352,9.15 - 9.59,9.2,0.0,0.0,29,18,finmb_314744798,NasdaqGS,"Gritstone bio, Inc.",USD,632979,609728,7.01,2.7598426,2.54 - 35.2,-25.650002,-0.7286932,2.54,35.2,1620291660,1620291660,1620291660,0.22881515,9.795073,-0.24507236,-0.025019964,-3.9139345,-1.449,-2.44,-1.27,-7.5196853,4.052,7.771714,1.778286,469839008,2.3568609,15,America/New_York,EDT,-14400000,False,False,0.11,,,35.2,2.54,7.77,9.8,632.98k,609.73k,49.2M,,37.47M,3.77%,70.97%,5.54M,11.22,13.76%,11.21%,4.82M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-157.14%,-157.42%,-23.84%,-51.21%,44.82M,0.78,482.60%,-84.61M,-64M,-70.44M,-1.45,,171.18M,3.46,22.35M,12.50,8.25,4.05,-57.42M,-35.29M,Value,94608,Healthcare,181,9,6,"Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was founded in 2015 and is headquartered in Emeryville, California.",EmeryVille,510 871 6100,CA,8,1609372800,1625097600,7,United States,http://gritstonebio.com,86400,8,5959 Horton Street,510 597 1488,Biotechnology,Suite 300
